Avanzanite Bioscience Reports European Commission's Authorisation of Orphan Medicinal Product AKANTIOR®

AMSTERDAM--(BUSINESS WIRE)-- #innovation--Avanzanite Bioscience B.V., a commercial-stage specialty pharmaceutical company, focused on bringing novel medicines for rare diseases to market, announced today that the European Commission (EC) granted marketing authorisation of AKANTIOR® (polihexanide) for the treatment of acanthamoeba keratitis (AK) in adults and children from 12 years of age. The formal approval by the EC follows previously reported positive opinion of the European Medicines Agency (EMA) Committ